What is Bioprotect?
Founded in 2004 and headquartered in Israel, Bioprotect specializes in the development and manufacturing of proprietary biodegradable implantable balloon solutions. These devices are engineered to protect healthy organs at risk during radiation oncology treatments, effectively minimizing collateral damage and improving patient outcomes. Beyond oncology, the company addresses critical surgical needs through its innovative material science applications. By positioning itself at the intersection of oncology and surgical intervention, Bioprotect has carved out a specialized niche, providing high-value solutions that address unmet clinical requirements in modern healthcare.
How much funding has Bioprotect raised?
Bioprotect has raised a total of $30.2M across 3 funding rounds:
Series C
$1.7M
Unspecified
$3.5M
Series D
$25M
Series C (2008): $1.7M with participation from Xenia Venture Capital
Unspecified (2017): $3.5M, investors not publicly disclosed
Series D (2020): $25M supported by Peregrine Ventures, Consensus Business Group, KB Investments, and Accelmed Ventures
Key Investors in Bioprotect
Xenia Venture Capital
A publicly traded investment firm on the Tel Aviv Stock Exchange, Xenia specializes in high-tech and med-tech sectors, providing comprehensive support through its technological incubator and strategic counseling.
Peregrine Ventures
Peregrine is a dedicated life science investor that leverages deep industry knowledge to support companies from early-stage development through to commercialization, focusing on groundbreaking healthcare technologies.
Consensus Business Group
An investment group providing strategic capital to support the growth and development of innovative enterprises within the medical and technology sectors.
What's next for Bioprotect?
With the recent capital infusion, Bioprotect is well-positioned to transition into a phase of aggressive commercial expansion and product diversification. The strategic focus will likely center on scaling manufacturing capabilities to meet global demand while simultaneously pursuing regulatory approvals in new international markets. Furthermore, the company is expected to leverage its strong investor base to foster collaborative research initiatives, potentially exploring new applications for its biodegradable technology platform. As the firm matures, the emphasis will shift toward long-term sustainability and the solidification of its market leadership in the radiation oncology space, ensuring that its innovative implants become a standard of care in surgical and oncological procedures worldwide.
See full Bioprotect company page
